CClinicalTrials.gg
CompletedNCT03058796Updated Jan 5, 2024Results posted

Contralaterally Controlled Functional Electrical Stimulation Plus Video Games for Hand Therapy After Stroke

A Phase 2 interventional study of Contralaterally Controlled Functional Electrical Stimulation (CCFES) and Hand Therapy Video Games in Upper Extremity Hemiplegia and Stroke, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

Determine if adding a video game component to an electrical stimulation therapy improves hand function in stroke patients

Read the detailed description

A single-blinded randomized controlled trial will be carried out to assess the effects of 12 weeks of Contralaterally Controlled Functional Electrical Stimulation (CCFES) +Hand Therapy Video Games (HTVG) compared to CCFES. Dexterity and activity limitation will be assessed at 0 (baseline), 12 (end of treatment), and 36 (6 months follow-up) wks. The planned treatment dose will be the same for both groups: 10 sessions per week of self-administered treatment at home plus 20 sessions of group-specific occupational therapy in the lab over 12 weeks.

02

Conditions studied

  • Upper Extremity Hemiplegia
  • Stroke

Keywords

  • stroke
  • rehabilitation
  • Hemiplegia
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 52 is close to the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,733 studies on the registry; 396 are open to participants now.

Of its 206 completed or terminated interventional studies of FDA-regulated products, 180 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

-> 6 months since a first clinical cortical or subcortical, hemorrhagic or nonhemorrhagic stroke

  • age 21-80 years old
  • unilateral upper limb hemiparesis with finger extensor strength of grade \<=4/5 on the Medical Research Council (MRC) scale AND a score of >=1 and \<=11/14 on the hand section of the upper extremity Fugl-Meyer Assessment
  • adequate active movement of the shoulder and elbow to position the hand in the workspace for table-top task practice (necessary for the lab task practice sessions)
  • able to follow 3-stage commands
  • able to recall 2 of 3 words after 30 minutes
  • surface stimulation of the paretic finger and thumb extensors produces functional hand opening without pain (this will exclude those who have degree of flexor hypertonia that prevents stimulated hand opening)
  • Functional passive range of motion (minimal resistance) at elbow, wrist, fingers, and thumb, i.e., there exists enough passive range of motion to reach and acquire table-top objects
  • intact vision and hearing
  • medically stable
  • full voluntary opening/closing of the contralateral (less affected) hand
  • demonstrate ability to follow instructions for operating the stimulator or have a caregiver who will assist them

Exclusion criteria

Exclusion Criteria:

  • co-existing neurologic diagnosis of peripheral nerve injury, Parkinson's disease, spinal cord injury, traumatic brain injury, or multiple sclerosis
  • uncontrolled seizure disorder
  • severely impaired cognition and communication
  • uncompensated hemineglect
  • arm or forearm skin breakdown or edema (to avoid edema-related shunting of current)
  • insensate forearm (to avoid risk of electrical burns)
  • history of potentially fatal cardiac arrhythmias with hemodynamic instability
  • implanted electronic systems (e.g. pacemaker)
  • botulinum toxin injections to any upper extremity muscle within 3 months of enrolling
  • pregnant women due to unknown risks of surface stimulation during pregnancy
  • participating in occupational therapy or other rehabilitation therapies to the upper extremity
  • severe shoulder or hand pain
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    CCFES Therapy

    CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.

    Device: Contralaterally Controlled Functional Electrical Stimulation (CCFES)

  • Experimental
    CCFES Video Game Therapy

    CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.

    Device: Contralaterally Controlled Functional Electrical Stimulation (CCFES) · Device: Hand Therapy Video Games

Interventions

  • DeviceContralaterally Controlled Functional Electrical Stimulation (CCFES)

    The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.

    Also known as: CCFES

  • DeviceHand Therapy Video Games

    The use of video games with CCFES to encourage therapeutic hand movement at home

    Also known as: HTVG

06

What researchers measure

Primary outcomes

  1. Box and Block Test Score

    The Box and Blocks Test counts how many blocks a patient can pick up, move over a barrier, and release in 60 seconds.

    Time frame: 0 weeks,12 weeks, 36 weeks

Secondary outcomes

  1. Action Research Arm Test (ARAT) Score

    The ARAT is an activity limitation measure that assesses a subject's ability to handle objects differing in size, weight and shape. Min value = 0 (least functional), Max value = 57 (most functional)

    Time frame: 0 weeks, 12 weeks, 36 weeks

07

Results

Posted Jan 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneCCFES Video Game TherapyCCFES Therapy
Started2725
Completed1821
Not completed94

Outcome measures

PrimaryBox and Block Test Score

The Box and Blocks Test counts how many blocks a patient can pick up, move over a barrier, and release in 60 seconds.

Time frame:
0 weeks,12 weeks, 36 weeks
Reported as:
Least squares mean · blocks
Box and Block Test Score
blocksCCFES Video Game TherapyCCFES Therapy
0 weeks10.6 ± 2.611.0 ± 2.6
12 weeks11.2 ± 2.812.4 ± 2.8
36 weeks11.1 ± 2.711.6 ± 2.6
SecondaryAction Research Arm Test (ARAT) Score

The ARAT is an activity limitation measure that assesses a subject's ability to handle objects differing in size, weight and shape. Min value = 0 (least functional), Max value = 57 (most functional)

Time frame:
0 weeks, 12 weeks, 36 weeks
Reported as:
Least squares mean · units on a scale
Action Research Arm Test (ARAT) Score
units on a scaleCCFES Video Game TherapyCCFES Therapy
0 weeks19.4 ± 3.619.0 ± 2.6
12 weeks18.6 ± 3.521.2 ± 2.8
36 weeks18.8 ± 3.720.6 ± 2.8

Adverse events

Collected over Adverse events were collected from the time of baseline assessment (0 weeks) until the end of study participation, typically 9 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CCFES Video Game Therapy0/27 (0%)3/27 (11.1%)8/27 (29.6%)
CCFES Therapy0/25 (0%)2/25 (8%)7/25 (28%)
Most frequent serious events
Most frequent serious events
EventCCFES Video Game TherapyCCFES Therapy
Fall leading to hospitalizationNervous system disorders2/271/25
Infection leading to hospitalizationRespiratory, thoracic and mediastinal disorders0/271/25
Car Accident leading to hospitalizationMusculoskeletal and connective tissue disorders1/270/25
Most frequent other events
Most frequent other events
EventCCFES Video Game TherapyCCFES Therapy
Fall not leading to hospitalizationNervous system disorders8/277/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)CCFES Video Game TherapyCCFES TherapyTotal
Mean60 ± 1162 ± 1161 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)CCFES Video Game TherapyCCFES TherapyTotal
Female91019
Male181533
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CCFES Video Game TherapyCCFES TherapyTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander101
Black or African American121022
White121224
More than one race000
Unknown or Not Reported213
Years Since Stroke
Years Since Stroke(years)CCFES Video Game TherapyCCFES TherapyTotal
Mean5 ± 4.53.9 ± 3.44.5 ± 4.0
08

Study locations

1 site
  • Louis Stokes VA Medical Center, Cleveland, OH
    Cleveland, Ohio 44106, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 8, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03058796
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Jun 19, 2017
Primary completion
Jun 13, 2022
Completion
Sep 30, 2022
Results posted
Jan 5, 2024
Last update
Jan 5, 2024

Study contacts

Jayme S. Knutson, PhD
principal investigator · Louis Stokes VA Medical Center, Cleveland, OH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion